目的:观察GDP方案(GEM+DDP+DXM)治疗复发性或难治性非霍奇金淋巴瘤的疗效和不良反应.方法:2008年1月至2010年3月安徽医科大学附属六安医院肿瘤中心收治的23例复发性或难治性非霍奇金淋巴瘤患者,给予吉西他滨(GEM) 1000 mg/m2 静脉滴注,d1,8;顺铂(DDP) 25mg/m2 静脉滴注,d1-3;地塞米松(DXM) 20-40mg静脉滴注,d1-3,21天为1周期,2个周期后评价疗效,并随访疾病进展情况.结果:23例患者中,14例缓解(60.9%),其中完全缓解5例(21.7%),部分缓解9例(39.1%).23例患者中位肿瘤进展时间(TTP)为5.0个月(95%CI:3-8个月).主要不良反应为骨髓抑制和轻中度消化道反应.骨髓抑制表现为3-4级白细胞减少2例;3-4级血红蛋白减少1例;3-4级血小板减少1例,并发出血.结论:GDP方案治疗复发性或难治性非霍奇金淋巴瘤是一个有效,相对不良反应较轻的二线挽救方案.%Objective:To evaluate the efficacy and side effects of chemotherapy with GDP regimen in patients with relapsed or refractory Non - Hodgkin's lymphoma. Methods: Twenty - three patients with relapsed or refractory non - Hodgkin's lymphoma were enrolled from January 2008 to March 2010. They received gemcitabine 1000mg/m2 , d1 ,ds and cisplatin 25mg/m2 , d1 - d3 , in combination with dexamethasone 20 -40mg d1 - d3 every 21 days. Efficacy assessment was conducted after two cycles therapy. Results: Among 23 patients,5 cases achieved complete response ( 21.7％ ) and 9 cases achieved partial response ( 39.1％ ). The median time to progression ( TTP ) was 5 months ( 95％ C1:3 -8 months ). The major adverse events were mild to moderate gastrointestinal reaction and nyelosuppression which included 2 cases of grade 3 -4 leukopenia and lcase of grade 4 thrombopenia with hemorrhage and 1 case of grade 3 - 4 hemophthisis. Conclusion: GDP regimen is effective and well - tolerated for relapsed or refractory non - Hodgkin's lymphoma.
展开▼
